Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (1340)	7/13/2000 2:01:42 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 52153

Jim, the rights to the derivatives were not included in the original Merz deal. But, when I've asked about their status, NTII just chuckles. They are focused on late stage development and don't intend to be around long enough to develop molecules that are still in preclinical development. The only value that the derviatives may have to NTII is as some extra spice to add to the deal when Freiman sits down with prospective buyers. Best regards John de C